![]() |
![]() |
In association with
|
|
Forward to a colleague |
||
Access Full Stories Bristol-Myers Squibb (BMS) has finally detailed its plans to trim the fat and save cash, months after first revealing that big changes would be on the cards... Read Abbott cuts jobs, closes plant in Ireland Abbott is to shut its doors on its Galway, Ireland, facility - taking 500 jobs with it - as the market moves into murky waters over the future of vascular stents... Read DSM and Arch go for API manufacturing deal DSM Anti-Infectives has signed up India's Arch Pharmalabs in a multi-year contract to manufacture generic active pharmaceutical ingredients (APIs)... Read Arius and Avid team up Arius Research and Avid Bioservices have joined forces in the manufacturing and development of an anticancer antibody... Read Separating mixtures in an NMR machine Canadian researchers have devised a method of extracting the complete proton NMR (nuclear magnetic resonance) spectra for a component of a mixture without the need for physical separation... Read |
||||||||||||||||||
All News Headlines for: December | November | October |
||||||||||||||||||
Transdermal Sufentanil Licensing Opportunity Aveva's 7-day sufentanil's advanced technology and patient benefits will enable Aveva and its Partner to capture a significant share of the existing $3.9 billion dollar chronic pain market... Click Here | ||||||||||||||||||
|
Related Industry News Microfluidics promises a bright future for cell-based assays UK researchers have published results that show that microfluidic devices can provide robust quantitative pharmacological information from low numbers of single cells... Read Genetic 'ID cards' enable meat traceability A new genetic identity test that can be used to confirm the breed and origin of meat from farm animals has been developed to enable complete meat traceability... Read Eisai selects Singapore as Asia trials hub Eisai is planning to step up its clinical research presence in Asia and has chosen Singapore as a hub from which to coordinate its research activities... Read Morphosys to exit fee-for-service upon Novartis deal Morphosys has landed in the money after scoring a lucrative 10 year antibody development deal with Novartis and as a result, will now place all its eggs in one basket and cut ties with its fee-for-service customers... Read
|
||||||||||||||||||
|
|||||
Forward to a colleague |
|||||
To continue to receive this newsletter in your inbox, please add newsletter@In-PharmaTechnologist.com to your address book |
||
Update preferences | Change your email address | Unsubscribe |
||
Contact us: Advertising | Recruitment | Privacy policy | Terms & conditions | Feedback |
||
| © 2007 - Decision News Media S.A.S - All Rights Reserved Le Belem - 355, rue Vendemiaire - 34000 Montpellier - France http://www.decisionnewsmedia.com |
||